|
1
|
Cancer Information Service, . Cancer
Statistics in Japan-2014. http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2014_jp.htmlMarch
14–2016
|
|
2
|
National Comprehensive Cancer Network
(NCCN), . NCCN Clinical Practice Guidelines in Oncology: Head and
Neck Cancers, Ver. 1. 2012.http://www.nccn.org/clinical.aspMarch
14–2016
|
|
3
|
Inagi K, Takahashi H, Okamoto M, Nakayama
M, Makoshi T and Nagai H: Treatment effects in patients with
squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl.
547:25–29. 2002. View Article : Google Scholar
|
|
4
|
Okada F, Hosokawa M, Hamada JI, Hasegawa
J, Kato M, Mizutani M, Ren J, Takeichi N and Kobayashi H: Malignant
progression of a mouse fibrosarcoma by host cells reactive to a
foreign body (gelatin sponge). Br J Cancer. 66:635–639. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishikawa M, Hosokawa M, Oh-hara N, Niho Y
and Kobayashi H: Marked granulocytosis in C57BL/6 mice bearing a
transplanted BMT-11 fibrosarcoma. J Natl Cancer Inst. 78:567–571.
1987.PubMed/NCBI
|
|
6
|
Kuramitsu Y, Hayashi E, Okada F, Tanaka T,
Zhang X, Ueyama Y and Nakamura K: Proteomic analysis for nuclear
proteins related to tumour malignant progression: A comparative
proteomic study between malignant progressive cells and regressive
cells. Anticancer Res. 30:2093–2099. 2010.PubMed/NCBI
|
|
7
|
Kuramitsu Y, Hayashi E, Okada F, Zhang X,
Ueyama Y and Nakamura K: Two-dimensional gel electrophoresis using
immobilized pH gradient strips and flamingo™ fluorescent gel stain
identified non-nuclear proteins possibly relates to tumor malignant
progression. Anticancer Res. 31:1259–1263. 2011.PubMed/NCBI
|
|
8
|
Hayashi E, Kuramitsu Y, Okada F, Fujimoto
M, Zhang X, Kobayashi M, Iizuka N, Ueyama Y and Nakamura K:
Proteomic profiling for cancer progression: Differential display
analysis for the expression of intracellular proteins between
regressive and progressive cancer cell lines. Proteomics.
5:1024–1032. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sheng W, Chen C, Dong M, Zhou J, Liu Q,
Dong Q and Li F: Overexpression of calreticulin contributes to the
development and progression of pancreatic cancer. J Cell Physiol.
229:887–897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Michalak M, Groenendyk J, Szabo E, Gold LI
and Opas M: Calreticulin, a multi-process calcium-buffering
chaperone of the endoplasmic reticulum. Biochem J. 417:651–666.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alur M, Nguyen MM, Eggener SE, Jiang F,
Dadras SS, Stern J, Kimm S, Roehl K, Kozlowski J, Pins M, et al:
Suppressive roles of calreticulin in prostate cancer growth and
metastasis. Am J Pathol. 175:882–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu R, Gong J, Chen J, Li Q, Song C, Zhang
J, Li Y, Liu Z, Dong Y, Chen L and Jin B: Calreticulin as a
potential diagnostic biomarker for lung cancer. Cancer Immunol
Immunother. 61:855–864. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kageyama S, Isono T, Iwaki H, Wakabayashi
Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y and Yoshiki T:
Identification by proteomic analysis of calreticulin as a marker
for bladder cancer and evaluation of the diagnostic accuracy of its
detection in urine. Clin Chem. 50:857–866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Erić A, Juranić Z, Milovanović Z, Marković
I, Inić M, Stanojević-Bakić N and Vojinović-Golubović V: Effects of
humoral immunity and calreticulin overexpression on postoperative
course in breast cancer. Pathol Oncol Res. 15:89–90. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM,
Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H and Chang KJ: Identification
of calreticulin as a prognosis marker and angiogenic regulator in
human gastric cancer. Ann Surg Oncol. 16:524–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoon GS, Lee H, Jung Y, Yu E, Moon HB,
Song K and Lee I: Nuclear matrix of calreticulin in hepatocellular
carcinoma. Cancer Res. 60:1117–1120. 2000.PubMed/NCBI
|
|
17
|
Brünagel G, Shah U, Schoen RE and
Getzenberg RH: Identification of calreticulin as a nuclear matrix
protein associated with human colon cancer. J Cell Biochem.
89:238–243. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chao MP, Jaiswal S, Weissman-Tsukamoto R,
Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB,
Raveh T, Park CY, et al: Calreticulin is the dominant
pro-phagocytic signal on multiple human cancers and is
counterbalanced by CD47. Sci Transl Med. 2:63ra942010. View Article : Google Scholar : PubMed/NCBI
|
